These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3622303)

  • 21. In vivo inhibition of hepatic lipogenesis in the rat by cyclandelate (3,3',5-trimethylcyclohexanylmandelate).
    Middleton A; White DA; Bell GD; Middleton B
    Biochem Pharmacol; 1983 Oct; 32(20):3079-83. PubMed ID: 6639676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The inhibition of hepatic S-3-hydroxy-3-methylglutaryl-CoA reductase by 3,3,5-trimethylcyclohexanol and its mandelic acid ester, cyclandelate.
    Middleton B; Middleton A; Miciak A; White DA; Bell GD
    Biochem Pharmacol; 1983 Feb; 32(4):649-51. PubMed ID: 6681959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of early diabetic retinopathy with cyclandelate.
    Cunha-Vaz JG; Reis Fonseca J; Hagenouw JR
    Br J Ophthalmol; 1977 Jun; 61(6):399-404. PubMed ID: 326306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Metabolites of cyclandelate. Vasodilator action and inhibition of phosphodiesterase by metabolites of cyclandelate].
    Himber J; De Burlet G; Andermann G
    Ann Pharm Fr; 1987; 45(3):233-41. PubMed ID: 3434974
    [No Abstract]   [Full Text] [Related]  

  • 25. Determination of plasma concentrations of cyclandelate and mandelic acid in patients with generalized atherosclerotic vasculopathy treated with oral cyclandelate.
    Forconi S; Cappelli R; Guerrini M; Volpi L; Frigerio C; Di Perri T
    J Int Med Res; 1990; 18(4):266-72. PubMed ID: 2227073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of cyclandelate in depressed and demented patients: a controlled study in psychogeriatric patients.
    Davies G; Hamilton S; Hendrickson E; Levy R; Post F
    Age Ageing; 1977 Aug; 6(3):156-62. PubMed ID: 331919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specific effects of cyclandelate on memory.
    Ananth J
    Drugs; 1987; 33 Suppl 2():97-102. PubMed ID: 3622311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of cerebral circulatory drugs on cerebral and peripheral circulation, with special reference to aminophylline, papaverine, cyclandelate and isoxsuprine.
    Miyazaki M
    Eur Neurol; 1971-1972; 6(1):162-5. PubMed ID: 5153420
    [No Abstract]   [Full Text] [Related]  

  • 29. Cyclandelate in the treatment of cerebral arteriosclerosis.
    Hall P
    J Am Geriatr Soc; 1976 Jan; 24(1):41-5. PubMed ID: 811704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of various therapeutic agents on cerebral and peripheral circulation--aminophylline, papaverine, cyclandelate and isoxsuprine].
    Miyazaki M
    Naika; 1972 Mar; 29(3):531-4. PubMed ID: 5035841
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical efficacy and central mechanisms of cyclandelate in migraine: a double-blind placebo-controlled study.
    Siniatchkin M; Gerber WD; Vein A
    Funct Neurol; 1998; 13(1):47-56. PubMed ID: 9584874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Letter: Cyclandelate and improved brain function.
    Wechsler AF
    Am J Psychiatry; 1974 Jun; 131(6):723. PubMed ID: 4827806
    [No Abstract]   [Full Text] [Related]  

  • 33. Inhibition of atherosclerosis in the rabbit by cyclandelate.
    Middleton A; Edwards E; White DA; Middleton B
    Br J Clin Pract Suppl; 1984; 34():39-42. PubMed ID: 6430322
    [No Abstract]   [Full Text] [Related]  

  • 34. Action of cyclandelate on the development of collateral vessels in the rabbit.
    van Hell G
    Curr Med Res Opin; 1974; 2(4):211-7. PubMed ID: 4841308
    [No Abstract]   [Full Text] [Related]  

  • 35. Cyclandelate versus flunarizine. A double-blind study in a selected group of patients with dementia.
    Albizzati MG; Bassi S; Calloni E; Sbacchi M; Piolti R; Frattola L
    Drugs; 1987; 33 Suppl 2():90-6. PubMed ID: 3304956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Use of a product of esterification of mandelic acid with 3,5,5-triethylcyclohexanol (cyclospasmol) in the treatment of peripheral arteriopathy].
    STARACE G; NOFERI A; PADULA R
    Gazz Med Ital; 1960 Apr; 119():133-6. PubMed ID: 13833815
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of cyclandelate on diabetic peripheral neuropathy.
    Canal N; Comi G; Marchettini P; Pozza G
    Br J Clin Pract Suppl; 1984; 34():62-8. PubMed ID: 6430326
    [No Abstract]   [Full Text] [Related]  

  • 38. Chronic cerebrovascular disorders: a clinical study with cyclandelate.
    Bassi S; Albizzati MG; Sbacchi M; Frattola L
    Br J Clin Pract; 1984 Oct; 38(10):344-9. PubMed ID: 6498057
    [No Abstract]   [Full Text] [Related]  

  • 39. Cyclandelate in diabetic radiculoneuropathy.
    van der Drift JH
    Ann Neurol; 1980 Apr; 7(4):388. PubMed ID: 7377764
    [No Abstract]   [Full Text] [Related]  

  • 40. Perceived efficacy of cyclandelate in the treatment of cochleovestibular and retinal disturbances related to cerebrovascular insufficiency. A study in general practice comprising 2772 patients.
    Memin Y
    Drugs; 1987; 33 Suppl 2():120-4. PubMed ID: 3497796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.